| Autor: |
Arguello-Tomas, Miguel, Albiol, Nil, Moreno, Carol |
| Zdroj: |
Acta Haematologica; 2024, Vol. 147 Issue 1, p49-61, 13p |
| Abstrakt: |
Background: The treatment landscape of chronic lymphocytic leukemia (CLL) has tremendously evolved in the last decades, thanks to the introduction of more effective therapies. Summary: Frontline therapy for patients with CLL includes chemoimmunotherapy (CIT) and pathway inhibitors (PIs) (i.e., bruton tyrosine kinase inhibitors and BCL2 inhibitors); the latter has proved to be more effective than CIT mainly in patients with high-risk features (e.g., TP53 aberrations and unmutated IGHV) with acceptable toxicity. Combinations of PIs are playing the protagonist role as frontline therapy for CLL. Key Messages: In this article, the management of treatment-naïve patients with CLL is discussed. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
